Gonorrhoea
9
0
0
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
11.1%
1 terminated out of 9 trials
88.9%
+2.4% vs benchmark
11%
1 trials in Phase 3/4
63%
5 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (9)
Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination
Clinical Study of a Single-Use, Point-of-Care Molecular Diagnostic Device for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) Utilizing Vaginal Swabs
Rapid Diagnosis of Antibiotic Resistance in Gonorrhoea
A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers
Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin
The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study
Cefixime / Azithromycin pK Study
Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea
Efficacy of Combination Therapies for Gonorrhea Treatment